The data include encouraging new imaging results from a post-hoc analysis of a randomized, double-bl

New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therap

Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Techn

A BioMarin combination therapy helped adults with late-onset Pompe disease maintain walking distance

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data evaluating the efficacy and safe

Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe dise

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $BMRN--Profluent, the frontier AI lab for biology, today ann

BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) and Metagenomi (NASDAQ: MGX - Get Free Repo

Q4 2026/ 2027 will be rich in catalysts for BioMarin Pharmaceutical Inc. From the presentation of 12

BioMarin Pharmaceutical NASDAQ: BMRN said it is progressing with the integration of Amicus Therapeut

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues othe

On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue

BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Confere

SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) annou

Amundi lifted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 37.8% during the

BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Tra

BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conf

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMR

BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transc

Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, r

Martin Shkreli calls Ultragenyx undervalued and a takeover target as the stock tanks after a trial f

Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare C

Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Over

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline cata

Jefferies analyst Akash Tewari maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and rai

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 poi

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of A

BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting Bi

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it has entered into binding terms wi

Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and pri

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Chec

BMO Capital analyst David Lebowitz initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) wi

BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BioMarin has entered into a definiti

Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Over

Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight a

Canaccord Genuity analyst Whitney Ijem maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Ov

Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outper

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN

BioMarin Pharmaceutical (NASDAQ:BMRN) raises FY2026 Adj EPS guidance from $4.85-$5.05 to $4.90-$5.10

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $1.20 per share which beat the

Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strengt

Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page

BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory fili